Literature DB >> 19137310

Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation.

A R Gillams1, W R Lees.   

Abstract

There is little published long-term survival data for patients with colorectal liver metastases treated with radiofrequency ablation (RFA). We present a multivariate analysis of 5-year survival in 309 patients (198 male, aged 64 (24-92)) treated at 617 sessions. Our standard protocol used internally cooled electrodes introduced percutaneously under combined US and CT guidance/monitoring. The number and size of liver metastases, the presence and location of extrahepatic disease, primary resection, clinical, chemotherapy and follow-up data were recorded. Data analysis was performed using SPSS v.10. On multivariate analysis, significant survival factors were the presence of extrahepatic disease (p < 0.001) and liver tumour volume (p = 0.001). For 123 patients with five or less metastases of 5 cm or less maximum diameter and no extrahepatic disease median survival was 46 and 36 months from liver metastasis diagnosis and ablation, respectively; corresponding 3- and 5-year survival rates were 63%, 34% and 49%, 24%. Sixty-nine patients had three or less tumours of below 3.5 cm in diameter and their 5-year survival from ablation was 33%. There were 23/617(3.7%) local complications requiring intervention. Five-year survival of 24-33% post ablation in selected patients is superior to any published chemotherapy data and approaches the results of liver resection.

Entities:  

Mesh:

Year:  2009        PMID: 19137310     DOI: 10.1007/s00330-008-1258-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

Review 1.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman
Journal:  Radiology       Date:  2005-04-21       Impact factor: 11.105

2.  Radio-frequency ablation of colorectal liver metastases in 167 patients.

Authors:  A R Gillams; W R Lees
Journal:  Eur Radiol       Date:  2004-07-27       Impact factor: 5.315

3.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

5.  Determinants of survival following hepatic resection for metastatic colorectal cancer.

Authors:  E A Bakalakos; J A Kim; D C Young; E W Martin
Journal:  World J Surg       Date:  1998-04       Impact factor: 3.352

6.  Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases.

Authors:  D Elias; J-F Ouellet; N Bellon; J-P Pignon; M Pocard; P Lasser
Journal:  Br J Surg       Date:  2003-05       Impact factor: 6.939

7.  Internally cooled power laser for MR-guided interstitial laser-induced thermotherapy of liver lesions: initial clinical results.

Authors:  T J Vogl; M G Mack; A Roggan; R Straub; K C Eichler; P K Müller; V Knappe; R Felix
Journal:  Radiology       Date:  1998-11       Impact factor: 11.105

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Patient selection for hepatic resection of colorectal metastases.

Authors:  H J Wanebo; Q D Chu; M P Vezeridis; C Soderberg
Journal:  Arch Surg       Date:  1996-03

10.  A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.

Authors:  S Cascinu; R Berardi; S Salvagni; G D Beretta; V Catalano; F Pucci; A Sobrero; P Tagliaferri; R Labianca; M Scartozzi; F Crocicchio; E Mari; A Ardizzoni
Journal:  Br J Cancer       Date:  2007-12-04       Impact factor: 7.640

View more
  87 in total

1.  Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates.

Authors:  Ayumi Hamada; Koichiro Yamakado; Atsuhiro Nakatsuka; Junji Uraki; Masataka Kashima; Haruyuki Takaki; Takashi Yamanaka; Yasuhiro Inoue; Masato Kusunoki; Kan Takeda
Journal:  Jpn J Radiol       Date:  2012-06-05       Impact factor: 2.374

Review 2.  Complications after percutaneous ablation of liver tumors: a systematic review.

Authors:  Eylon Lahat; Rony Eshkenazy; Alex Zendel; Barak Bar Zakai; Mayan Maor; Yael Dreznik; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

3.  Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).

Authors:  T Ruers; C Punt; F Van Coevorden; J P E N Pierie; I Borel-Rinkes; J A Ledermann; G Poston; W Bechstein; M A Lentz; M Mauer; E Van Cutsem; M P Lutz; B Nordlinger
Journal:  Ann Oncol       Date:  2012-03-19       Impact factor: 32.976

4.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention.

Authors:  A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

5.  The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis.

Authors:  H H Tam; D J Collins; G Brown; I Chau; D Cunningham; M O Leach; D-M Koh
Journal:  Br J Radiol       Date:  2013-08-30       Impact factor: 3.039

6.  Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.

Authors:  Kim Sivesgaard; Lars P Larsen; Michael Sørensen; Stine Kramer; Sven Schlander; Nerijus Amanavicius; Arindam Bharadwaz; Dennis Tønner Nielsen; Frank Viborg Mortensen; Erik Morre Pedersen
Journal:  Eur Radiol       Date:  2018-05-07       Impact factor: 5.315

Review 7.  Lesion discrimination with breath-hold hepatic diffusion-weighted imaging: a meta-analysis.

Authors:  Zhi-Guang Chen; Li Xu; Si-Wei Zhang; Yan Huang; Rui-Huan Pan
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

8.  Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases.

Authors:  Xiaodong Wang; Constantinos T Sofocleous; Joseph P Erinjeri; Elena N Petre; Mithat Gonen; Kinh G Do; Karen T Brown; Anne M Covey; Lynn A Brody; William Alago; Raymond H Thornton; Nancy E Kemeny; Stephen B Solomon
Journal:  Cardiovasc Intervent Radiol       Date:  2012-04-26       Impact factor: 2.740

Review 9.  Thermal Ablation in the Management of Colorectal Cancer Patients with Oligometastatic Liver Disease.

Authors:  Elena Nadia Petre; Constantinos Sofocleous
Journal:  Visc Med       Date:  2017-02-03

10.  Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression.

Authors:  Elena A Kaye; Francois H Cornelis; Elena N Petre; Neelam Tyagi; Waleed Shady; Weiji Shi; Zhigang Zhang; Stephen B Solomon; Constantinos T Sofocleous; Jeremy C Durack
Journal:  Eur Radiol       Date:  2018-11-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.